Start: January 25, 2021
End: December 1, 2025
This Phase 1 study will evaluate the safety and feasibility of using [18F]3F4AP as a positron emission tomography (PET) tracer to detect the breakdown of neurons, called neurodegeneration, in the brains of people with mild cognitive impairment (MCI), Alzheimer's disease, or traumatic brain injury (TBI). All participants will receive an injection of [18F]3F4AP followed by a PET scan and MRI of the brain. Participants with Alzheimer's, MCI, or TBI will also undergo neuropsychological testing. Researchers will assess the distribution of the tracer in the body using a CT scan and monitor all participants for any adverse events for five years. The results of this study may be used to develop new tools to diagnose neurodegenerative diseases and conditions.
Minimum Age: 18 Years
Maximum Age: 90 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Massachusetts General Hospital
Boston, MA 02114
RecruitingMarina Macdonald-Soccorso, BS
Lead: Massachusetts General Hospital
Source: ClinicalTrials.gov ID: NCT04710550